Journal article
Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer
Abstract
PURPOSE: Intravenous delivery of oncolytic viruses often leads to tumor vascular shutdown, resulting in decreased tumor perfusion and elevated tumor hypoxia. We hypothesized that using 3TSR to normalize tumor vasculature prior to administration of an oncolytic Newcastle disease virus (NDV) would enhance virus delivery and trafficking of immunologic cell subsets to the tumor core, resulting in systemically enhanced immunotherapy and regression …
Authors
Matuszewska K; Santry LA; van Vloten JP; AuYeung AWK; Major PP; Lawler J; Wootton SK; Bridle BW; Petrik J
Journal
Clinical Cancer Research, Vol. 25, No. 5, pp. 1624–1638
Publisher
American Association for Cancer Research (AACR)
Publication Date
March 1, 2019
DOI
10.1158/1078-0432.ccr-18-0220
ISSN
1078-0432
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Angiogenesis InhibitorsAnimalsCell Line, TumorCell SurvivalCombined Modality TherapyCytokinesDisease Models, AnimalFemaleGenetic VectorsHumansHypoxiaImmunomodulationInterferonsMiceNeoplasm StagingNeovascularization, PathologicOncolytic VirotherapyOncolytic VirusesOvarian NeoplasmsTransgenesTreatment OutcomeXenograft Model Antitumor Assays